| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.62 |
4.64e-2 |
79/89 (88.76%) |
CD28;HRAS;PPP3CC;...
|
| NF-kappa B signaling pathway |
-1.63 |
4.42e-2 |
90/104 (86.54%) |
CYLD;RIPK1;PLCG2;...
|
| Intestinal immune network for IgA production |
-1.64 |
4.20e-2 |
38/48 (79.17%) |
CD28;HLA-DQB1;PIGR;...
|
| Legionellosis |
-1.64 |
4.35e-2 |
51/57 (89.47%) |
IL1B;EEF1A2;HSPA1L;...
|
| Kaposi sarcoma-associated herpesvirus infection |
-1.66 |
3.93e-2 |
172/193 (89.12%) |
GABARAPL2;CCR4;LYN;...
|
| Th17 cell differentiation |
-1.66 |
3.60e-2 |
95/107 (88.79%) |
PLCG1;STAT5B;HLA-DOA;...
|
| NOD-like receptor signaling pathway |
-1.67 |
3.69e-2 |
145/181 (80.11%) |
GBP2;MAPK3;IL1B;...
|
| Staphylococcus aureus infection |
-1.67 |
3.73e-2 |
72/95 (75.79%) |
KRT33A;HLA-DOA;ITGAL;...
|
| Rheumatoid arthritis |
-1.73 |
2.13e-2 |
78/93 (83.87%) |
ATP6V1B2;CSF2;IL11;...
|
| Type I diabetes mellitus |
-1.74 |
1.98e-2 |
38/43 (88.37%) |
TNF;HLA-DOA;INS;...
|
| Cell adhesion molecules |
-1.77 |
1.61e-2 |
118/148 (79.73%) |
SDC3;ITGA6;SIGLEC1;...
|
| Viral myocarditis |
-1.77 |
1.77e-2 |
53/60 (88.33%) |
HLA-DOA;CAV1;ITGAL;...
|
| Antigen processing and presentation |
-1.80 |
1.54e-2 |
60/78 (76.92%) |
HLA-DQB1;KLRC3;NFYB;...
|
| Hematopoietic cell lineage |
-1.97 |
1.92e-3 |
90/99 (90.91%) |
CSF2;IL11;CR1;...
|
| Viral protein interaction with cytokine and cytokine re... |
-1.97 |
2.19e-3 |
84/100 (84%) |
IL20RA;CCL7;ACKR4;...
|
| Th1 and Th2 cell differentiation |
-1.98 |
1.28e-3 |
80/92 (86.96%) |
PLCG1;STAT4;STAT5B;...
|
| Graft-versus-host disease |
-2.00 |
0.00e+0 |
32/42 (76.19%) |
IL6;FAS;KIR3DL1;...
|
| Allograft rejection |
-2.04 |
0.00e+0 |
32/38 (84.21%) |
CD28;FASLG;HLA-DQB1;...
|
| IL-17 signaling pathway |
-2.08 |
0.00e+0 |
84/94 (89.36%) |
TRADD;CCL11;JUND;...
|
| Autoimmune thyroid disease |
-2.11 |
0.00e+0 |
46/53 (86.79%) |
CGA;CD28;FASLG;...
|
| Primary immunodeficiency |
-2.38 |
0.00e+0 |
33/38 (86.84%) |
CD79A;CD40LG;CD8B;...
|
